<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04296214</url>
  </required_header>
  <id_info>
    <org_study_id>HAL 318/2019</org_study_id>
    <nct_id>NCT04296214</nct_id>
  </id_info>
  <brief_title>Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia</brief_title>
  <official_title>Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Cooperativo de Hemopatías Malignas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Cooperativo de Hemopatías Malignas</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators want to compare the global response rate of patients with myelodysplastic
      syndrome (MDS) and acute myeloid leukemia (AML) after six months of treatment with
      5-azacitidine on two different doses. First group of 50 mg/m2 for 10 days each 28 days versus
      75 mg/m2 for 7 days on 28 days cycles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      5-Azacitidine it's the standard treatment for patients with MDS and it is widely used for AML
      in patients that aren't fit for intensive treatment. The standard dose of azacitidine is 75
      mg/m2 for 7 días on 28 days cycles. Nevertheless there are studies of pharmacokinetics that
      have showed there is no difference on plasmatic distribution between 25, 50, 75 or 100 mg/m2
      with similar concentration curves. The actual presentation of azacitidine is 100 mg per
      bottle with less of 24 hours of utility after opened. Looking for optimizations on the use of
      5-azacitidine, we have changed the dosing to 50 mg/m2 for 10 days on 28 days cycles with a
      total dose application of 95% of the traditional regimen with the saving of 5 bottles of the
      drug.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>6 months</time_frame>
    <description>Global response rate by International Criteria</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>Azacitidine 50 mg/m2 for 10 days each 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>Azacitidine 75 mg/m2 for 7 days each 28 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-azacitidine</intervention_name>
    <description>Cycles of 28 days</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Confirmed diagnosis of MDS that require treatment with 5-aza characterized by: i)
             RAEB-1 defined as the presence of 5%-9% of myeloblasts in bone marrow; ii) RAEB-2
             defined as the presence of 10%-19% of myeloblasts in bone marrow or 5%-19% blasts in
             peripheral blood; iii) IPSS-R very high, high or intermediate

          2. Confirmed AML with blasts ≥ 20% in bone marrow or peripheral blood and that its not
             candidate to receive intense chemotherapy at consideration of the physician.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Confirmed diagnosis of MDS that require treatment with 5-aza characterized by: i)
             RAEB-1 defined as the presence of 5%-9% of myeloblasts in bone marrow; ii) RAEB-2
             defined as the presence of 10%-19% of myeloblasts in bone marrow or 5%-19% blasts in
             peripheral blood; iii) IPSS-R very high, high or intermediate

          -  Confirmed AML with blasts ≥ 20% in bone marrow or peripheral blood and that its not
             candidate to receive intense chemotherapy at consideration of the physician.

          -  Performance status of 0, 1 o 2 by the Eastern Cooperative Oncology Group (ECOG).

          -  Availability to sign an informed consent

        Exclusion Criteria:

          -  Previous treatment for MDS or AML with chemotherapy or another antineoplastics
             including hypomethylating agents.

          -  Acute promyelocytic leukemia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Grupo Cooperativo de Hemopatías Malignas</name>
      <address>
        <city>Huixquilucan</city>
        <state>Estado De México</state>
        <zip>52763</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Ovilla-Martinez, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>ovillarob@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Pamela E Baez Islas, MD</last_name>
      <phone>(55)5246-5000</phone>
      <phone_ext>4830</phone_ext>
      <email>drabaez.hematologia@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 3, 2020</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 31, 2020</last_update_submitted>
  <last_update_submitted_qc>March 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

